These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34100235)

  • 21. Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
    Morkos M; Mahrous P; Casagrande A; Go MT; Husni H; Hanna M; Goel M; Bedrose S; Li D; Baim S
    Endocr Pract; 2022 Oct; 28(10):1078-1085. PubMed ID: 35787466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
    Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
    Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
    Mori T; Crandall CJ; Ganz DA
    Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
    Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
    Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
    Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
    J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
    Händel MN; Cardoso I; von Bülow C; Rohde JF; Ussing A; Nielsen SM; Christensen R; Body JJ; Brandi ML; Diez-Perez A; Hadji P; Javaid MK; Lems WF; Nogues X; Roux C; Minisola S; Kurth A; Thomas T; Prieto-Alhambra D; Ferrari SL; Langdahl B; Abrahamsen B
    BMJ; 2023 May; 381():e068033. PubMed ID: 37130601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Denosumab versus Bisphosphonates for Reducing Fractures in Postmenopausal Women with Osteoporosis: A Meta-Analysis.
    Thal KA; Nudy M; Moser EM; Foy AJ
    J Am Board Fam Med; 2023 Feb; 36(1):175-185. PubMed ID: 36653115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dispensing anti-osteoporotic drugs changed during the COVID-19 pandemic.
    Kocijan R; Stockinger T; Haschka J; Reichardt B; Resch H; Zwerina J; Behanova M
    Bone; 2022 Sep; 162():116477. PubMed ID: 35779846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
    Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
    Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
    Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
    J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
    Tai TW; Hwang JS; Li CC; Hsu JC; Chang CW; Wu CH
    J Bone Miner Res; 2022 Aug; 37(8):1520-1526. PubMed ID: 35689432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
    Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
    Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review.
    Elbers LPB; Raterman HG; Lems WF
    Drugs; 2021 Sep; 81(14):1645-1655. PubMed ID: 34524681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
    Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
    Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
    Langdahl B
    Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
    Ström O; Jönsson B; Kanis JA
    Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study.
    Lee H; Jin Y; Roh M; Tsacogianis TN; Park S; Choi NK; Kim SC
    Drugs Aging; 2020 Apr; 37(4):311-320. PubMed ID: 32026309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
    Singer AJ; Liu J; Yan H; Stad RK; Gandra SR; Yehoshua A
    Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.